This application will investigate the potential for nanomaterials to have adverse effects on human health and to formulate approaches to screen nanomaterials for potential health risks, particularly those with a high likelihood for human exposure in Australia. Understanding how existing nanomaterials interact with biological systems will help determine the risk of adverse effects in the human population and identify those nanoparticles with little or no risk.
Randomised Controlled Trial Of Intravenous Antivenom Versus Placebo In The Treatment Of Redback Spider Bite
Funder
National Health and Medical Research Council
Funding Amount
$487,440.00
Summary
Redback spiderbite is the most common significant envenoming in Australia and bites by the closely related widow spiders are a major global problem. Despite widespread use of redback spider antivenom, no controlled study has tested its effectiveness. This study aims to test the efficacy of antivenom versus placebo in a large multicentre, randomised controlled trial - RAVE-II. It is of critical importance to determine if an expensive treatment with a known risk of allergic reactions is effective.